argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia – Zai Lab Limited

Tuesday, March 26, 2024 1 min read

Key Takeaway: argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia – Zai Lab Limited

Full Press Release Details

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia – Zai Lab Limited.